Compare Stocks: APM, TVRD, BFRI, and COCP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.26	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
BFRI Biofrontera	$1.30 +3.2%	$1.08	$0.55 ▼ $1.40	$16.13M	0.78	388,241 shs	972,630 shs
COCP Cocrystal Pharma	$1.12 +1.8%	$0.99	$0.76 ▼ $2.67	$15.17M	1.43	70,708 shs	38,297 shs
TVRD Tvardi Therapeutics	$1.90 +7.3%	$2.49	$1.50 ▼ $43.65	$16.60M	0.39	513,662 shs	345,662 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	-91.80%	-91.89%	-95.30%
BFRI Biofrontera	+0.80%	+0.80%	+18.87%	+57.50%	+32.63%
COCP Cocrystal Pharma	-1.79%	+6.80%	+16.98%	-8.33%	-34.52%
TVRD Tvardi Therapeutics	0.00%	-4.32%	-42.90%	-55.75%	-92.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APM Aptorum Group	$0.67 -4.6%	$5.26	$0.60 ▼ $4.47	$4.24M	0.38	57,956 shs	167,078 shs
BFRI Biofrontera	$1.30 +3.2%	$1.08	$0.55 ▼ $1.40	$16.13M	0.78	388,241 shs	972,630 shs
COCP Cocrystal Pharma	$1.12 +1.8%	$0.99	$0.76 ▼ $2.67	$15.17M	1.43	70,708 shs	38,297 shs
TVRD Tvardi Therapeutics	$1.90 +7.3%	$2.49	$1.50 ▼ $43.65	$16.60M	0.39	513,662 shs	345,662 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APM Aptorum Group	0.00%	0.00%	-91.80%	-91.89%	-95.30%
BFRI Biofrontera	+0.80%	+0.80%	+18.87%	+57.50%	+32.63%
COCP Cocrystal Pharma	-1.79%	+6.80%	+16.98%	-8.33%	-34.52%
TVRD Tvardi Therapeutics	0.00%	-4.32%	-42.90%	-55.75%	-92.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APM Aptorum Group	1.00	Sell	N/A	N/A
BFRI Biofrontera	2.00	Hold	N/A	N/A
COCP Cocrystal Pharma	1.00	Sell	N/A	N/A
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	847.37% Upside

Current Analyst Ratings Breakdown

Latest APM, TVRD, BFRI, and COCP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/16/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/15/2026	BFRI Biofrontera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/8/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform	$10.00
7/8/2026	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$13.00
7/8/2026	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
7/7/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
7/3/2026	BFRI Biofrontera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
6/29/2026	APM Aptorum Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APM Aptorum Group	$430K	9.86	N/A	N/A	$2.17 per share	0.31
BFRI Biofrontera	$41.71M	0.40	N/A	N/A	$0.90 per share	1.44
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	$0.46 per share	N/A
TVRD Tvardi Therapeutics	$7.14M	2.50	N/A	N/A	$2.23 per share	0.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APM Aptorum Group	-$1.36M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	-$10.54M	-$0.97	N/A	21.67	N/A	-13.78%	-155.98%	-31.69%	N/A
COCP Cocrystal Pharma	-$8.83M	-$0.73	N/A	N/A	N/A	N/A	-164.57%	-108.08%	N/A
TVRD Tvardi Therapeutics	-$18.21M	-$3.10	N/A	N/A	N/A	N/A	-64.17%	-43.90%	N/A

Latest APM, TVRD, BFRI, and COCP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.69	-$0.04	-$0.69	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/13/2026	Q2 2026	COCP Cocrystal Pharma	-$0.17	-$0.23	-$0.06	-$0.23	$0.23 million	$0.11 million
5/15/2026	Q1 2026	COCP Cocrystal Pharma	-$0.15	-$0.17	-$0.02	-$0.17	$0.23 million	$0.23 million
5/14/2026	Q1 2026	BFRI Biofrontera	-$0.1150	-$0.41	-$0.2950	-$0.41	$10.25 million	$10.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APM Aptorum Group	N/A	N/A	N/A	N/A	N/A
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
COCP Cocrystal Pharma	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APM Aptorum Group	N/A	0.78	0.78
BFRI Biofrontera	0.78	1.20	1.09
COCP Cocrystal Pharma	N/A	2.66	2.66
TVRD Tvardi Therapeutics	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APM Aptorum Group	3.80%
BFRI Biofrontera	10.08%
COCP Cocrystal Pharma	6.72%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
APM Aptorum Group	63.99%
BFRI Biofrontera	8.10%
COCP Cocrystal Pharma	39.40%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APM Aptorum Group	30	6.35 million	2.29 million	Not Optionable
BFRI Biofrontera	70	12.80 million	11.77 million	No Data
COCP Cocrystal Pharma	10	13.79 million	8.36 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.38 million	8.69 million	N/A

APM, TVRD, BFRI, and COCP Headlines

Recent News About These Companies

Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

August 14 at 7:00 AM | globenewswire.com

Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026

August 12 at 8:00 AM | globenewswire.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

Tvardi Therapeutics Inc.

July 7, 2026 | cnn.com

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | finance.yahoo.com

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | globenewswire.com

TVRD Share News Today

June 29, 2026 | uk.investing.com

Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting

June 27, 2026 | theglobeandmail.com

Tvardi Therapeutics, Inc. Common Stock

June 27, 2026 | fxempire.comF

H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)

June 25, 2026 | theglobeandmail.com

Tvardi Therapeutics Shareholders Approve Directors and Governance Measures

June 11, 2026 | tipranks.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026 | globenewswire.com

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

May 13, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, TVRD, BFRI, and COCP Company Descriptions

Aptorum Group NASDAQ:APM

$0.67 -0.03 (-4.57%)

Closing price 07/17/2026

Extended Trading

$0.67 0.00 (0.00%)

As of 07/17/2026 07:46 PM Eastern

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.

Biofrontera NASDAQ:BFRI

$1.30 +0.04 (+3.17%)

Closing price 04:00 PM Eastern

Extended Trading

$1.32 +0.02 (+1.54%)

As of 07:45 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Cocrystal Pharma NASDAQ:COCP

$1.12 +0.02 (+1.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.09 -0.03 (-2.32%)

As of 07:54 PM Eastern

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Tvardi Therapeutics NASDAQ:TVRD

$1.90 +0.13 (+7.34%)

Closing price 04:00 PM Eastern

Extended Trading

$1.89 -0.01 (-0.47%)

As of 07:37 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, TVRD, BFRI, and COCP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, TVRD, BFRI, and COCP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, TVRD, BFRI, and COCP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, TVRD, BFRI, and COCP Company Descriptions

Aptorum Group NASDAQ:APM

Biofrontera NASDAQ:BFRI

Cocrystal Pharma NASDAQ:COCP

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APM, TVRD, BFRI, and COCP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APM, TVRD, BFRI, and COCP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APM, TVRD, BFRI, and COCP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APM, TVRD, BFRI, and COCP Company Descriptions

Aptorum Group NASDAQ:APM

Biofrontera NASDAQ:BFRI

Cocrystal Pharma NASDAQ:COCP

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools